Iterum Therapeutics plc ITRM 深 沪
等待开盘 08-15 09:30:00 美东时间
0.8163
0.000
-0.04%
华盛通- 最 高0.84
- 今 开0.84
- 成交量 65.90万股
- 最 低 0.80
- 昨 收 0.8166
- 总市值 3265.20万
- 52周最高 3.02
- 市盈率 静 --
- 换手率 1.65%
- 52周最低 0.6573
- 委 比 -29.08%
- 总股本 4000.00万
- 历史最高 195.00
- 量 比 0.72
- 振 幅 4.90%
- 历史最低 0.622
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CORRECTION: Iterum Therapeutics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate. Cash And Equivalents Of $13M, Runway Into 2026
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.48 percent increase over losses of $(0.23) per share
08-05 20:49
Iterum Therapeutics Non-GAAP EPS of -$0.13
Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13. Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects t...
08-05 19:16
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Insights Ahead: Iterum Therapeutics's Quarterly Earnings
Iterum Therapeutics (NASDAQ:ITRM) is preparing to release its quarterly earning...
08-05 05:03
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
Iterum Therapeutics plc, a company focused on developing next-generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens, announced it will release its second quarter 2025 financial results before the U.S. market opens on August 5, 2025. Management will host a conference call at 8:30 a.m. ET that day. To access the call, dial 833-470-1428 (domestic) or 404-975-4839 (international) with Access Code 740801. The ...
07-29 12:00
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics授予新任首席商业化官Christine Coyne 20万股股票期权，行权价为每股0.97美元，期权有效期10年，分四年归属，每年25%。期权授予基于Nasdaq新员工激励规定，经薪酬委员会批准。Iterum专注于开发抗生素治疗耐药感染，其主要产品sulopenem已获FDA批准用于治疗尿路感染。
07-02 20:30
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
Iterum Therapeutics appointed Christine Coyne as Chief Commercial Officer to lead the U.S. launch of ORLYNVAH™ and future commercialization efforts. With over 30 years of experience, Coyne brings significant expertise in anti-infectives, aiming to accelerate ORLYNVAH™'s success and long-term growth for the company. ORLYNVAH™ is an oral penem antibiotic targeting uUTIs caused by multi-drug resistant pathogens.
06-30 11:00
Iterum Shares Phase 3 Trial Results Showing How Its Oral Antibiotic Compares to Augmentin for UTIs
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community
06-25 19:06
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
Iterum Therapeutics reported that 9.2% of patients in the REASSURE trial had baseline pathogens resistant to three or more antibiotic classes. Results from the Phase 3 trial, published in *NEJM Evidence*, showed oral sulopenem was non-inferior and statistically superior to Augmentin® for treating uncomplicated urinary tract infections (uUTI), with a 61.7% success rate vs. 55.0%. The U.S. FDA approved ORLYNVAH™, an oral sulopenem, for uUTIs caused...
06-25 11:00
Iterum Therapeutics Announces Partnership for Commercialization Services
Iterum Therapeutics has partnered with EVERSANA to commercialize ORLYNVAH™, an oral penem antibiotic, in the U.S. by Q4 2025. The agreement includes sales, marketing, and logistics support. ORLYNVAH™ targets hard-to-treat uncomplicated urinary tract infections and marks the first oral penem available in the U.S. The companies aim to address antibiotic resistance and improve patient access to effective treatments. A conference call discussing this...
06-11 11:00
